Literature DB >> 19242073

Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study.

P R Chavan1, S V Chavan, N R Chavan, V D Trivedi.   

Abstract

BACKGROUND: Need for undertaking prostate biopsies for detection of prostate cancer is often decided on the basis of serum levels of prostate specific antigen (PSA). AIM: To evaluate the case detection rate of prostate cancer among patients presenting with lower urinary tract symptoms (LUTS) on the basis of PSA levels and to assess the scope of prostate biopsy in these patients. SETTING AND
DESIGN: A retrospective study from a tertiary care center.
MATERIALS AND METHODS: The clinical and histopathological data of 922 patients presenting with LUTS in the last five years was obtained from the medical record section. They had been screened for prostate cancer using PSA and /or digital rectal examination examination followed by confirmation with prostate biopsy. STATISTICAL ANALYSIS USED: Detection rate and receiver operating characteristic curve were performed using SPSS 16 and Medcalc softwares.
RESULTS: The detection rate of prostate cancer according to the PSA levels was 0.6%, 2.3%, 2.5%, 34.1% and 54.9% in the PSA range of 0-4, 4-10, 10-20, 20-50 and> 50 ng/ml, respectively. Maximum prostate cancer cases were detected beyond a PSA value of 20 ng/ml whereas no significant difference in the detection rate was observed in the PSA range of 0-4, 4-10 and 10-20 ng/ml.
CONCLUSION: A low detection rate of prostate cancer observed in the PSA range of 4-20 ng/ml in LUTS patients indicates the need for use of higher cutoff values of PSA in such cases. Therefore we recommend a cutoff of 20 ng/ml of PSA for evaluation of detection rate of prostate cancer among patients presenting with LUTS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242073     DOI: 10.4103/0022-3859.43548

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  11 in total

1.  TRUS Biopsy Yield in Indian Population: A Retrospective Analysis.

Authors:  Sunil Raghunath Patil; Prakash Wamanrao Pawar; Ajit Somaji Sawant; Akshay Vijay Patil; Sayalee Suryabhan Narwade; Shankar Tanaji Mundhe; Abhishek Jaysukhbhai Savalia; Ashwin Sunil Tamhankar
Journal:  J Clin Diagn Res       Date:  2017-02-01

2.  Outcomes of standard 12-core transrectal ultrasound-guided prostate biopsy in biopsy naive Indian men -single center experience.

Authors:  Abhishek Laddha; Appu Thomas; Deepak Chandran Nair; Greeshma C Ravindran; Ginil Kumar Pooleri
Journal:  Indian J Urol       Date:  2020-07-01

3.  A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml.

Authors:  Sushant V Chavan; Niraj R Chavan; Anusha Balaji; Vatsala D Trivedi; Padma R Chavan
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

4.  Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.

Authors:  Alexandre Peltier; Fouad Aoun; Vincent De Ruyter; Patrick Cabri; Roland Van Velthoven
Journal:  Prostate Cancer       Date:  2015-01-28

5.  Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.

Authors:  Ruizhe Zhao; Yuan Huang; Gong Cheng; Jinliang Liu; Pengfei Shao; Chao Qin; Lixin Hua; Changjun Yin
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

6.  The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.

Authors:  Zhi-Bing Wang; Chao-Gang Wei; Yue-Yue Zhang; Peng Pan; Guang-Cheng Dai; Jian Tu; Jun-Kang Shen
Journal:  Biomed Res Int       Date:  2021-10-11       Impact factor: 3.411

7.  Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer.

Authors:  Sushant V Chavan; Anurupa Maitra; Nobhojit Roy; Padma R Chavan
Journal:  Indian J Med Res       Date:  2014-03       Impact factor: 2.375

8.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26

9.  Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.

Authors:  Yuxiao Zheng; Yuan Huang; Gong Cheng; Cheng Zhang; Jie Wu; Chao Qin; Lixin Hua; Zengjun Wang
Journal:  Springerplus       Date:  2016-09-05

10.  An overview of serum prostatic surface antigen cut points for recommendation of prostatic biopsy.

Authors:  Sujata K Patwardhan; Bhushan P Patil; Umesh Ravikant Shelke; Abhishek G Singh
Journal:  Urol Ann       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.